FGFR inhibitor

DRUG CLASS:

FGFR inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C1 ASCO 2023 - 1wk	erdafitinib Sensitive: C1 - Off-label ASCO 2023 - 1 week erdafitinib Sensitive : C1 ASCO 2023 - 1 week - (New C3)
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C1 ASCO 2023 - 1wk	erdafitinib Sensitive: C1 - Off-label ASCO 2023 - 1 week erdafitinib Sensitive : C1 ASCO 2023 - 1 week - (New C3)
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	futibatinib Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) futibatinib Sensitive : C2 ASCO 2023 - 1wk	futibatinib Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week futibatinib Sensitive : C2 ASCO 2023 - 1 week - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	FGFR inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) FGFR inhibitor Sensitive : C3 ASCO 2023 - 1wk	FGFR inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 1 week FGFR inhibitor Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR2 fusion	Solid Tumor	FGFR2 fusion	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C3 ASCO 2023 - 1wk	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week erdafitinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR3 fusion	Solid Tumor	FGFR3 fusion	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C3 ASCO 2023 - 1wk	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week erdafitinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR1 fusion	Solid Tumor	FGFR1 fusion	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C3 ASCO 2023 - 1wk	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week erdafitinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C3 ASCO 2023 - 1wk	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week erdafitinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR mutation + PD-L1 expression	Urothelial Cancer	FGFR mutation + PD-L1 expression	Urothelial Cancer	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) erdafitinib + JNJ-63723283 Sensitive : C3 ASCO 2023 - 1wk	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials ASCO 2023 - 1 week erdafitinib + JNJ-63723283 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR1 mutation	Glioma	FGFR1 mutation	Glioma	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) erdafitinib Sensitive : C3 ASCO 2023 - 1wk	erdafitinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week erdafitinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	futibatinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) futibatinib Sensitive : C3 ASCO 2023 - 1wk	futibatinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week futibatinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR1 mutation	Solid Tumor	FGFR1 mutation	Solid Tumor	futibatinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) futibatinib Sensitive : C3 ASCO 2023 - 1wk	futibatinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week futibatinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 1 week (New C4) pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 1wk	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 1 week pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 1 week - (New C4)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1	futibatinib Sensitive: A1 - Approval futibatinib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1	pemigatinib Sensitive: A1 - Approval pemigatinib Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	everolimus + lenvatinib Sensitive: A2 - Guideline everolimus + lenvatinib Sensitive : A2	everolimus + lenvatinib Sensitive: A2 - Guideline everolimus + lenvatinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
RET fusion	Lung Cancer	RET fusion	Lung Cancer	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B
No biomarker	Cholangiocarcinoma	No biomarker	Cholangiocarcinoma	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B	infigratinib Sensitive: B - Late Trials infigratinib Sensitive : B
FGF21 elevation	Hepatocellular Cancer	FGF21 elevation	Hepatocellular Cancer	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B
VEGFA elevation	Hepatocellular Cancer	VEGFA elevation	Hepatocellular Cancer	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + lenvatinib Sensitive: B - Late Trials pembrolizumab + lenvatinib Sensitive : B	pembrolizumab + lenvatinib Sensitive: B - Late Trials pembrolizumab + lenvatinib Sensitive : B

FGFR inhibitor

FGFR inhibitor

Associations(400)

Associations
(400)